Compare BFLY & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | NEO |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Medical Electronics | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2008 |
| Metric | BFLY | NEO |
|---|---|---|
| Price | $4.42 | $8.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.00 | ★ $13.38 |
| AVG Volume (30 Days) | ★ 5.1M | 2.1M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.01 | $10.63 |
| Revenue Next Year | $19.93 | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $4.72 |
| 52 Week High | $5.72 | $13.74 |
| Indicator | BFLY | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 54.27 |
| Support Level | $3.63 | $8.68 |
| Resistance Level | $5.00 | $8.84 |
| Average True Range (ATR) | 0.34 | 0.43 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 40.24 | 41.77 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.